Cleared Traditional

K081674 - BINDAZYME HUMAN ANTI-GLIADIN (MGP), IGG EIA KIT

Also marketed or referenced as:
BINDAZYME HUMAN ANTI-GLIADIN (MGP) IGA EIA KIT (IGA OR IGG)

K081674 is an FDA 510(k) clearance for BINDAZYME HUMAN ANTI-GLIADIN (MGP), manufactured by The Binding Site, Ltd.. The device is a Class 2 Immunology device with product code MST cleared through the Traditional 510(k) pathway after a 120-day FDA review.

K081674 · The Binding Site, Ltd. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2008
Decision
120d
Days
Class 2
Risk

K081674 is an FDA 510(k) clearance for the BINDAZYME HUMAN ANTI-GLIADIN (MGP), IGG EIA KIT. Classified as Antibodies, Gliadin (product code MST), Class II - Special Controls.

Submitted by The Binding Site, Ltd. (Santa Monica, US). The FDA issued a Cleared decision on October 15, 2008 after a review of 120 days - within the typical 510(k) review window.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5750 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all The Binding Site, Ltd. devices

FDA 510(k) Submission Details - K081674

510(k) Number K081674 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 17, 2008
Decision Date October 15, 2008
Days to Decision 120 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
15d slower than avg
Panel avg: 105d · This submission: 120d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

MST Device Classification - Class 2, Special Controls

Product Code MST Antibodies, Gliadin
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5750
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - MST Antibodies, Gliadin

All 33
Devices cleared under the same product code (MST) and FDA review panel - the closest regulatory comparables to K081674.
IMMULISA CELIAC G+ (GLIADIN) IGA AND IGG ANTIBODY ELISA
K091522 · Immco Diagnostics, Inc. · Feb 2010
EUROIMMUN ANTI-GLIADIN (GAF-3X) ELISA (IGG)
K083053 · Euroimmun Us, Inc. · Aug 2009
EUROIMMUN ANTI-GLIADIN (GAF-3X) ELISA (IGA)
K083052 · Euroimmun Us, Inc. · Jul 2009
ELIA GLIADIN IGA, IGG AND CELIAC CONTROL
K063775 · Phadia US, Inc. · Mar 2007
QUANTA LITE H-TTG/DGP SCREEN
K070083 · Inova Diagnostics, Inc. · Mar 2007
QUANTA LITE CELIAC DGP SCREEN
K062708 · Inova Diagnostics, Inc. · Dec 2006